ARX788 clinical trials
Also written ARX788.
How each study uses ARX788 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ARX788 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2021 (4)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2021 | 4 |
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 7
Ambrx, Inc. (3) · Fudan University (3) · Caigang Liu (1) · Henan Cancer Hospital (1) · Laura Huppert, MD, BA (1) · QuantumLeap Healthcare Collaborative (1) · Zhejiang Medicine Co., Ltd. (1)
Often tested with
Tested in the same studies.
Trastuzumab (1) · Ganitumab (1) · Ado-Trastuzumab Emtansine (1) · Pertuzumab (1) · STA 9090 (1) · Veliparib (1) · Neratinib (1) · Pexidartinib (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test ARX788.
- Dec 2026ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)Phase 2 · Ambrx, Inc.
- Nov 2027ARX788 in HER2-positive Metastatic Breast Cancer PatientsPhase 2 · Henan Cancer Hospital
Studies
Open first, then newest update. How each study uses ARX788 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 11
- ARX788 in HER2-positive Metastatic Breast Cancer PatientsRecruitingPhase 2Henan Cancer HospitalNCT06663748Written as ARX788
- ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast CancerRecruitingPhase 2Laura Huppert, MD, BANCT06224673Written as ARX788
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingPhase 2QuantumLeap Healthcare CollaborativeNCT01042379Written as ARX788
- ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXdNot yet recruitingPhase 2Fudan UniversityNCT06578286Written as ARX788
- ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)Active, not recruitingPhase 2Ambrx, Inc.NCT04829604Written as ARX788
- A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer PatientsActive, not recruitingPhase 2/3Caigang LiuNCT05426486Written as ARX788
- A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)CompletedPhase 1Ambrx, Inc.NCT03255070Written as ARX788
- ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)WithdrawnPhase 2Ambrx, Inc.NCT05041972Written as ARX788
- ARX788 in HER2-positive Breast Cancer Patients With Brain MetastasesStatus unknownPhase 2Fudan UniversityNCT05018702Written as ARX788
- ARX788 in Breast Cancer With Low Expression of HER2Status unknownPhase 2Fudan UniversityNCT05018676Written as ARX788
- A Dose-escalation Study of ARX788, IV Administered in Subjects With Advanced Cancers With HER2 ExpressionTerminatedPhase 1Zhejiang Medicine Co., Ltd.NCT02512237Written as ARX788
Codes
What other systems call ARX788 · ClinicalTrials.gg INT001432
- MeSH (NLM) C000710874ARX788One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000710874 | ARX788 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.